Novo Nordisk to slash prices of weightloss drugs in US / Photo: SCOTT OLSON - GETTY IMAGES NORTH AMERICA/AFP/File
-
Sinner stops Jodar to book spot in Madrid Open semis
-
Pogacar wins opening full stage to take Tour de Romandie lead
-
'River on fire': Toxic fumes as Ukrainian drones pound Russian oil town
-
Pereira aiming to bring European glory back to Forest
-
Uber adds hotel booking in push to become 'everything app'
-
Oil spikes while stocks slip ahead of US Fed rate decision
-
Two Jewish men stabbed in 'terrorist' attack in London
-
End of an era: last hereditary peers exit UK parliament
-
Canada holds key rate steady, says will act if war inflation persists
-
Emery aims to write 'new chapter' in Europe with Villa
-
US Supreme Court curbs race-based voting maps in landmark ruling
-
Guerrillas claim deadly Colombia attack, say it was an 'error'
-
Trump warns Iran better 'get smart soon' and accept nuclear deal
-
UN experts urge Saudi labour practices switch before World Cup
-
Oil spikes while stocks slide ahead of US Fed rate decision
-
US Fed chief's plans in focus as central bank set to hold rates steady
-
King Charles to visit 9/11 memorial in New York
-
Tuareg rebels vow Mali junta 'will fall', north will be captured
-
German inflation jumps in April as energy costs surge
-
Was PSG against Bayern the Champions League's greatest ever game?
-
UBS first-quarter profits jump 80% on investment banking
-
European stocks fall with eyes on earnings, US Fed
-
France's 'roadmap' to exit fossil fuels by 2050
-
Chelsea captain Millie Bright retires
-
Bangladesh measles outbreak kills over 220 children since March
-
Mercedes warns longer Mideast war could cause shortages
-
Finnish lift maker Kone acquires German rival TKE, creating giant
-
Hungary's Magyar visits Brussels seeking to unblock EU billions
-
Diving robot explores mystery of France's deepest shipwreck
-
Thai ex-PM Thaksin to be released from prison next month
-
Welsh rugby great North to hang up his boots
-
Much-needed rains revive Iraq's fabled Mesopotamian Marshes
-
French teen in straw licking case allowed to leave Singapore
-
EU chief says Kremlin imposing 'digital Iron Curtain' on Russians
-
South Korean court hikes ex-president's sentence for obstructing justice
-
Adidas reports higher profits but warns of 'volatile' climate
-
TotalEnergies first-quarter profits surge amid Middle East war
-
Sri Lanka government 'temporarily' takes over cricket board
-
EU finds Meta failing to keep under-13s off Facebook, Instagram
-
Oil rises further with Iran war peace talks stalled
-
King Charles to stress UK-US cultural, trade ties in New York
-
US judge orders Purdue Pharma to pay billions ahead of bankruptcy
-
'Jurassic Park' star Sam Neill says cancer-free after gene therapy
-
US opioid crisis victims testify at emotional Purdue Pharma hearing
-
Australian climber on record sea-to-summit Everest bid
-
Indian opposition slams Nicobar megaport plan as 'destruction'
-
Pentagon chief to testify on Iran war, peace efforts stall
-
Anxiety, resentment around AI spur violence against tech's figureheads
-
Mercedes-Benz profit slides amid cutthroat Chinese market
-
Hungary's Magyar to push post-Orban EU reset on Brussels visit
NYSE - LSE
Novo Nordisk to slash prices of weightloss drugs in US
Danish drugmaker Novo Nordisk, which is struggling with competition for its anti-obesity treatments, said Tuesday that it will sharply cut prices for its flagship drugs in the US, announcing a 50 percent cut for Wegovy and 35 percent for Ozempic.
"This decision applies to all doses of these medicines and reflects Novo Nordisk's commitment to enhancing affordability for patients and both public and private payers dealing with the complexities of the evolving US healthcare system," the company said in a statement.
Effective January 1, 2027, the list price will be $675 for a month's worth of Wegovy, which currently costs around $1,350 a month.
Ozempic and Rybelsus, treatments that each currently come to about $1,000, will also be priced $675.
Novo Nordisk said the price reduction is meant to make it possible to reach more patients.
"Lowering the list price of Wegovy and Ozempic is the best approach to address the unprecedented opportunity to help more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the United States," Jamey Millar, executive vice president of Novo Nordisk's US Operations, said.
In early February, Novo Nordisk vowed legal against US chain Hims & Hers for offering a copycat of the new pill version of Wegovy.
Limited production capacity for the blockbuster drug led the FDA to temporarily allow pharmacies to create so-called "compound" or copycat versions of Wegovy and Ozempic, an analogue used to treat diabetes.
That authorisation expired last May 22 but Novo Nordisk has complained of copycat versions of its drugs still being available.
Ozempic is an injectable anti-diabetic treatment that became popular on social media for its slimming properties.
Wegovy, which has the same active ingredient as Ozempic in a different dose, is a weight-loss drug and is also available in pill form.
Both treatments use analogues of the hormone GLP-1, which regulates blood glucose levels and appetite.
Shares in Novo Nordisk have taken a beating in recent weeks after it warned in early February of lower sales revenue in the United States as intensified competition pushes down prices.
They fell 3.8 percent in afternoon trading in Copenhagen.
O.Salim--SF-PST